Back to Search Start Over

WNT Pathway Mutations in Metachronous Oligometastatic Castration-Sensitive Prostate Cancer.

Authors :
Sutera, Philip
Deek, Matthew P.
Van der Eecken, Kim
Shetty, Amol C.
Chang, Jin Hee
Hodges, Theresa
Song, Yang
Verbeke, Sofie
Van Dorpe, Jo
Fonteyne, Valérie
De Laere, Bram
Mishra, Mark
Rana, Zaker
Molitoris, Jason
Ferris, Matthew
Ross, Ashley
Schaeffer, Edward
Roberts, Nicholas
Song, Daniel Y.
DeWeese, Theodore
Source :
International Journal of Radiation Oncology, Biology, Physics. Apr2023, Vol. 115 Issue 5, p1095-1101. 7p.
Publication Year :
2023

Abstract

WNT signaling is a cellular pathway that has been implicated in the development and progression of prostate cancer. Oligometastatic castration-sensitive prostate cancer (omCSPC) represents a unique state of disease in which metastasis-directed therapy (MDT) has demonstrated improvement in progression-free survival. Herein, we investigate the clinical implications of genomic alterations in the WNT signaling cascade in men with omCSPC. We performed an international multi-institutional retrospective study of 277 men with metachronous omCSPC who underwent targeted DNA sequencing of their primary/metastatic tumor. Patients were classified by presence or absence of pathogenic WNT pathway mutations (in the genes APC, RNF43, and CTNNB1). Pearson χ2 and Mann-Whitney U tests were used to determine differences in clinical factors between genomic strata. Kaplan-Meier survival curves were generated for radiographic progression-free survival and overall survival, stratified according to WNT pathway mutation status. A pathogenic WNT pathway mutation was detected in 11.2% of patients. Patients with WNT pathway mutations were more likely to have visceral metastases (22.6% vs 2.8%; P <.01) and less likely to have regional lymph node metastases (29.0% vs 50.4%; P =.02). At time of oligometastasis, these patients were treated with MDT alone (33.9%), MDT + limited course of systemic therapy (20.6%), systemic therapy alone (22.4%), or observation (defined as no treatment for ≥6 months after metastatic diagnosis). Multivariable cox regression demonstrated WNT pathway mutations associated with significantly worse overall survival (hazard ratio, 3.87; 95% confidence interval, 1.25-12.00). Somatic WNT pathway alterations are present in approximately 11% of patients with omCSPC and are associated with an increased likelihood of visceral metastases. Although these patients have a worse natural history, they may benefit from MDT. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
03603016
Volume :
115
Issue :
5
Database :
Academic Search Index
Journal :
International Journal of Radiation Oncology, Biology, Physics
Publication Type :
Academic Journal
Accession number :
162177873
Full Text :
https://doi.org/10.1016/j.ijrobp.2022.12.006